Cargando…
Post COVID-19 condition of the Omicron variant of SARS-CoV-2
OBJECTIVES: To investigate the prevalence of post coronavirus disease (COVID-19) condition of the Omicron variant in comparison to other strains. STUDY DESIGN: A single-center cross-sectional study. METHODS: Patients who recovered from Omicron COVID-19 infection (Omicron group) were interviewed via...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365517/ https://www.ncbi.nlm.nih.gov/pubmed/35963600 http://dx.doi.org/10.1016/j.jiac.2022.08.007 |
_version_ | 1784765355106762752 |
---|---|
author | Morioka, S. Tsuzuki, S. Suzuki, M. Terada, M. Akashi, M. Osanai, Y. Kuge, C. Sanada, M. Tanaka, K. Maruki, T. Takahashi, K. Saito, S. Hayakawa, K. Teruya, K. Hojo, M. Ohmagari, N. |
author_facet | Morioka, S. Tsuzuki, S. Suzuki, M. Terada, M. Akashi, M. Osanai, Y. Kuge, C. Sanada, M. Tanaka, K. Maruki, T. Takahashi, K. Saito, S. Hayakawa, K. Teruya, K. Hojo, M. Ohmagari, N. |
author_sort | Morioka, S. |
collection | PubMed |
description | OBJECTIVES: To investigate the prevalence of post coronavirus disease (COVID-19) condition of the Omicron variant in comparison to other strains. STUDY DESIGN: A single-center cross-sectional study. METHODS: Patients who recovered from Omicron COVID-19 infection (Omicron group) were interviewed via telephone, and patients infected with other strains (control group) were surveyed via a self-reporting questionnaire. Data on patients’ characteristics, information regarding the acute-phase COVID-19, as well as presence and duration of COVID-19-related symptoms were obtained. Post COVID-19 condition in this study was defined as a symptom that lasted for at least 2 months, within 3 months of COVID-19 onset. We investigated and compared the prevalence of post COVID-19 condition in both groups after performing propensity score matching. RESULTS: We conducted interviews for 53 out of 128 patients with Omicron and obtained 502 responses in the control group. After matching cases with controls, 18 patients from both groups had improved covariate balance of the factors: older adult, female sex, obesity, and vaccination status. There were no significant differences in the prevalence of each post COVID-19 condition between the two groups. The number of patients with at least one post COVID-19 condition in the Omicron and control groups were 1 (5.6%) and 10 (55.6%) (p = 0.003), respectively. CONCLUSIONS: The prevalence of post Omicron COVID-19 conditions was less than that of the other strains. Further research with a larger sample size is needed to investigate the precise epidemiology of post COVID-19 condition of Omicron, and its impact on health-related quality of life and social productivity. |
format | Online Article Text |
id | pubmed-9365517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93655172022-08-11 Post COVID-19 condition of the Omicron variant of SARS-CoV-2 Morioka, S. Tsuzuki, S. Suzuki, M. Terada, M. Akashi, M. Osanai, Y. Kuge, C. Sanada, M. Tanaka, K. Maruki, T. Takahashi, K. Saito, S. Hayakawa, K. Teruya, K. Hojo, M. Ohmagari, N. J Infect Chemother Original Article OBJECTIVES: To investigate the prevalence of post coronavirus disease (COVID-19) condition of the Omicron variant in comparison to other strains. STUDY DESIGN: A single-center cross-sectional study. METHODS: Patients who recovered from Omicron COVID-19 infection (Omicron group) were interviewed via telephone, and patients infected with other strains (control group) were surveyed via a self-reporting questionnaire. Data on patients’ characteristics, information regarding the acute-phase COVID-19, as well as presence and duration of COVID-19-related symptoms were obtained. Post COVID-19 condition in this study was defined as a symptom that lasted for at least 2 months, within 3 months of COVID-19 onset. We investigated and compared the prevalence of post COVID-19 condition in both groups after performing propensity score matching. RESULTS: We conducted interviews for 53 out of 128 patients with Omicron and obtained 502 responses in the control group. After matching cases with controls, 18 patients from both groups had improved covariate balance of the factors: older adult, female sex, obesity, and vaccination status. There were no significant differences in the prevalence of each post COVID-19 condition between the two groups. The number of patients with at least one post COVID-19 condition in the Omicron and control groups were 1 (5.6%) and 10 (55.6%) (p = 0.003), respectively. CONCLUSIONS: The prevalence of post Omicron COVID-19 conditions was less than that of the other strains. Further research with a larger sample size is needed to investigate the precise epidemiology of post COVID-19 condition of Omicron, and its impact on health-related quality of life and social productivity. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022-11 2022-08-11 /pmc/articles/PMC9365517/ /pubmed/35963600 http://dx.doi.org/10.1016/j.jiac.2022.08.007 Text en © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Morioka, S. Tsuzuki, S. Suzuki, M. Terada, M. Akashi, M. Osanai, Y. Kuge, C. Sanada, M. Tanaka, K. Maruki, T. Takahashi, K. Saito, S. Hayakawa, K. Teruya, K. Hojo, M. Ohmagari, N. Post COVID-19 condition of the Omicron variant of SARS-CoV-2 |
title | Post COVID-19 condition of the Omicron variant of SARS-CoV-2 |
title_full | Post COVID-19 condition of the Omicron variant of SARS-CoV-2 |
title_fullStr | Post COVID-19 condition of the Omicron variant of SARS-CoV-2 |
title_full_unstemmed | Post COVID-19 condition of the Omicron variant of SARS-CoV-2 |
title_short | Post COVID-19 condition of the Omicron variant of SARS-CoV-2 |
title_sort | post covid-19 condition of the omicron variant of sars-cov-2 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365517/ https://www.ncbi.nlm.nih.gov/pubmed/35963600 http://dx.doi.org/10.1016/j.jiac.2022.08.007 |
work_keys_str_mv | AT moriokas postcovid19conditionoftheomicronvariantofsarscov2 AT tsuzukis postcovid19conditionoftheomicronvariantofsarscov2 AT suzukim postcovid19conditionoftheomicronvariantofsarscov2 AT teradam postcovid19conditionoftheomicronvariantofsarscov2 AT akashim postcovid19conditionoftheomicronvariantofsarscov2 AT osanaiy postcovid19conditionoftheomicronvariantofsarscov2 AT kugec postcovid19conditionoftheomicronvariantofsarscov2 AT sanadam postcovid19conditionoftheomicronvariantofsarscov2 AT tanakak postcovid19conditionoftheomicronvariantofsarscov2 AT marukit postcovid19conditionoftheomicronvariantofsarscov2 AT takahashik postcovid19conditionoftheomicronvariantofsarscov2 AT saitos postcovid19conditionoftheomicronvariantofsarscov2 AT hayakawak postcovid19conditionoftheomicronvariantofsarscov2 AT teruyak postcovid19conditionoftheomicronvariantofsarscov2 AT hojom postcovid19conditionoftheomicronvariantofsarscov2 AT ohmagarin postcovid19conditionoftheomicronvariantofsarscov2 |